Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of LU901 (4-phenylbutyrate) plus hormonal therapy in metastatic prostate carcinoma
2010-020681-16Phase 2Active
- Sponsor
- Lunamed
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of phenylbutyric acid in prostate cancer (PCa), sponsored by Lunamed. Primary endpoints: Tumor progression, Complete clinical response rate and 1 more. Started Jul 2010; status: active.
02
Drugs
phenylbutyric acid
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2010-020681-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020681-16.